Home
About Us
Help and Support
Subscribe
Company Analyst
Financial Analyst
Pipeline Analyst
Archives
Tools
Log In
Print this
Letermovir (AIC246, MK-8228)
print preview
bookmark
share with colleague
General Information
Company
AiCuris GmbH & Co. KG
Description
Quinazoline-based inhibitor of the cytomegalovirus (CMV) terminase protein
Molecular Target
Mechanism of Action
Latest Stage of Development
Phase II
Indication
Cytomegalovirus (CMV)
Partner
Merck & Co. Inc.
Product Summary: Number of Indications in each Phase of Development by Disease Category
More
Product Details
Archive Items are loading
Set Email Alert
dummy
General Information